JCV Antibody Program in Patients w/Relapsing MS & who are Receiving or Considering Tx with Tysabri

JCV Antibody Program in patients with Relapsing MS and who are Receiving or Considering Treatment with Tysabri

Type of Study
Neuroscience - Multiple Sclerosis
Location
Cherry Hill Campus
Short Description

Multiple Sclerosis (MS) patients taking Tysabri have an increased risk of developing Progressive Multifocal Leukoencephalopathy (PML), a type of brain infection.  The JC virus is associated with PML.  This study measures the antibodies to the JC virus in blood samples taken from MS patients who are taking Tysabri to investigate the possibility of a correlation between the presence or absence of the JC virus antibodies and a higher or lower risk of getting PML.

Status
Open
Principal Investigator
Lily Jung, MD
Eligibility Notes

Inclusion Criteria:

Potential study patients must have

     *relapsing Multiple Sclerosis

     *must be receiving Tysabri

     *or considering treatment with Tysabri

 

Exclusion Criteria:

Patients participating in any other Tysabri clinical trial or study sponsored by Biogen, Idec, or Elan.

Contact Name
Lily Jung, MD
Phone
206-320-2800
Alternate Phone
206-320-7115
Email
lily.jung@swedish.org
Alternate Email
becky.wood@swedish.org